Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.56 |
| ▸ | HTR3B | O95264 | 3/20 | 0.56 |
| ▸ | HTR3A | P46098 | 3/20 | 0.56 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.56 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.55 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | PNMT | P11086 | 1/20 | 0.48 |
| ▸ | NAAA | Q02083 | 2/20 | 0.48 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.47 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.47 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.47 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.47 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.47 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3030059 | 1.00 | HTR3E (0.56) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL7740676 | 1.00 | HTR3E (0.56) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL1047900 | 0.98 | HTR3E (0.58) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL82224 | 0.92 | HTR3E (0.59) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL31567921 | 0.90 | TAAR1 (0.65) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL2176833 | 0.86 | CYP4F2 (0.56) | CYP4F2CYP4A11TBXA2R | |
| SCHEMBL12040536 | 0.84 | TAAR1 (0.59) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL625264 | 0.84 | TAAR1 (0.63) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL5241228 | 0.83 | TAAR1 (0.68) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL238401 | 0.83 | CYP4F2 (0.58) | CYP4F2CYP4A11TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3277665-B1 | INDOLE ANALOGS AS 5-OXO-ETE RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIV (CA) | 2020-03-04 | — | — | EP | disclosed |
| US-20180086702-A1 | INDOLE ANALOGS AS 5-OXO-ETE RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2018-03-29 | — | — | US | disclosed |
| WO-2016154749-A1 | INDOLE ANALOGS AS 5-OXO-ETE RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2016-10-06 | — | — | WO | disclosed |
| US-20150224099-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OTSUKA PHARMA CO LTD (JP) | 2015-08-13 | — | — | US | disclosed |
| US-8987304-B2 | Antituberculous composition comprising oxazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-03-24 | — | — | US | disclosed |
| EP-2269694-A2 | Antituberculous composition comprising oxazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-01-05 | — | — | EP | disclosed |
| US-20090275528-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-11-05 | — | — | US | disclosed |
| EP-1028955-B1 | PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITHKLINE BEECHAM PLC (GB) | 2003-07-16 | — | — | EP | disclosed |
| US-6417192-B1 | DRUGS WITH PYRIMIDONE COMPOUNDS INHIBITORS OF THE ENZYME LDL PLA.SUB.2 AND THEREFORE OF USE IN TREATING ATHEROSCLEROSIS. | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150224099-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OXA1L, ARG1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HTR3E 4362/4885HTR3B 3377/4885HTR3A 4208/4885 |
| US-20090275528-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OXA1L, ARG1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HTR3E 4362/4885HTR3B 3377/4885HTR3A 4208/4885 |
| US-20180086702-A1 | INDOLE ANALOGS AS 5-OXO-ETE RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF | HTR5A, EDNRA, HTR3E | HTR3E 3/4885HTR3B 12/4885HTR3A 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.